Abstract
Heart of Darkness: The Downside of Trastuzumab
Highlights
Trastuzumab has been shown to be quite effective in reducing suffering and mortality from breast cancer in both the metastatic[1] and adjuvant settings.[2,3,4,5]
With short follow-up, remarkably consistent results across five adjuvant, prospective, randomized clinical trials suggest that trastuzumab may decrease the odds of distant recurrence and mortality by approximately one half and one third, respectively
Dr George Sledge, who discussed the first presentations of the adjuvant trials at the 2005 Annual Meeting of the American Society of Clinical Oncology, proclaimed these results “astonishing,” and we agree
Summary
“Heart of Darkness: The Downside of Trastuzumab.”. Journal of Clinical Oncology 24 (25) (August 14): 4056–4058.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
